Skip to main content
Clinical Trials/NCT02746198
NCT02746198
Completed
Not Applicable

A Randomized Double-blind Placebo-controlled Clinical Pilot Trial on the Effect of a Probiotic Fermented Drink on Antibiotic-associated Diarrhea (AAD) in Patients With Helicobacter Pylori Eradication Therapy

Clinical Research Center Kiel GmbH1 site in 1 country125 target enrollmentJanuary 22, 2016

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Antibiotic-associated Diarrhea
Sponsor
Clinical Research Center Kiel GmbH
Enrollment
125
Locations
1
Primary Endpoint
Occurrence of antibiotic-associated diarrhea (AAD)
Status
Completed
Last Updated
5 years ago

Overview

Brief Summary

The aim of the study is to estimate the effect of a probiotic dairy drink on occurrence and duration of AAD and gastrointestinal symptoms during Helicobacter pylori (Hp) eradication therapy and during 4 weeks thereafter and calculating the sample size for a confirmatory study.

Detailed Description

Helicobacter p. positive subjects aged ≥18 years with an indication for Helicobacter pylori (Hp) eradication recommended by a gastroenterologist should be included in the study. Subjects should be willing to consume 2 servings of the study product per day for 6 weeks, and to undergo an Hp eradication therapy for 14 days starting with the consumption period.

Registry
clinicaltrials.gov
Start Date
January 22, 2016
End Date
April 26, 2017
Last Updated
5 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Sponsor
Clinical Research Center Kiel GmbH
Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Individuals, both genders, aged ≥ 18 y
  • Helicobacter p. infected individuals, to which eradication therapy has been recommended by gastroenterologists
  • Willingness to undergo the Helicobacter p. eradication therapy
  • Willingness to abstain from food and supplements containing probiotics, prebiotics and fermented products except the study product
  • Written informed consent

Exclusion Criteria

  • Subjects currently enrolled in another interventional trial
  • subjects having finished another interventional trial within the last 4 weeks before inclusion
  • incapacity to comply with the study protocol
  • allergy or hypersensitivity to any component of the test product (allergy against milk protein)
  • allergy or hypersensitivity to any component of the eradication therapy (e.g. penicillin allergy)
  • acute GIT infections
  • chronic inflammatory bowel diseases (IBD)
  • irritable bowel syndrome (IBS)
  • any episode of diarrhea according to WHO criteria during the last 4 weeks before inclusion
  • history of lactose intolerance

Outcomes

Primary Outcomes

Occurrence of antibiotic-associated diarrhea (AAD)

Time Frame: 6 weeks

Occurrence of antibiotic-associated diarrhea (AAD) (as defined by number of subjects with diarrhea within the intervention period of 6 weeks after starting antibiotic treatment; diarrhea is defined according WHO

Secondary Outcomes

  • Cumulative sverity of antibiotic-associated diarrhea (AAD)(6 weeks)
  • Gastrointestinal Symptom Rating Scale(6 weeks)
  • Cumulated duration of antibiotic-associated diarrhea (AAD)(6 weeks)

Study Sites (1)

Loading locations...

Similar Trials